Delcath Systems (NasdaqCM:DCTH) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker6Greetings, welcome to Delcath Systems' fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone key, keypad. Please note this conference is being recorded. It is now my pleasure to turn the c ...

Core Viewpoint - The article discusses a securities class action against Zynex, Inc. due to allegations of false and misleading statements regarding the company's business practices and financial reporting, with a deadline for investors to seek lead plaintiff status set for April 21, 2026 [1]. Group 1: Allegations Against Zynex - Zynex allegedly shipped products in excess of need, inflating its revenue [1][2] - The company faced scrutiny from insurers, including Tricare, for filing false claims [1][2] - A lawsuit was filed by Travelers against Zynex and its executives, seeking over $23 million in damages for fraudulent claims between 2018 and 2023 [1][2] - Management prioritized aggressive sales strategies over compliance with industry regulations [1][2] - The company was not committed to maintaining a strong internal control environment [1][2] - Order growth was attributed to illegal overbilling practices [1][2] - There is a reasonable likelihood of adverse consequences for Zynex, including removal from insurer networks and federal penalties [1][2] - Positive statements made by the defendants about the company's operations were materially misleading [1][2] Group 2: Financial Impact and Stock Performance - On March 11, 2025, Zynex reported a significant revenue shortfall due to slower payments from payers, leading to a stock price drop of $3.59 per share, or 51.3%, closing at $3.41 per share [1][2] - On July 31, 2025, Zynex acknowledged non-compliance with industry regulations, resulting in a stock decline from $2.23 per share to $1.26 per share, a 45% drop [1][2] Group 3: Legal Proceedings and Investor Actions - The court-appointed lead plaintiff will be the investor with the largest financial interest who directs the litigation on behalf of the class [1][2] - Any member of the class may move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1][2] - Faruqi & Faruqi, LLP encourages individuals with information regarding Zynex's conduct to come forward [1][2]

Anika Therapeutics (NasdaqGS:ANIK) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker4Good morning, ladies and gentlemen, and welcome to Anika's fourth quarter and year-end earnings conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, February 26, 2026. I would now ...

Group 1: Intuitive Surgical Overview - Intuitive Surgical is a leader in surgical robotics, primarily due to its da Vinci surgical systems, with 11,106 systems installed by the end of 2025, reflecting a 12% year-over-year increase [2] - The number of surgeries performed using da Vinci systems increased by 18% year-over-year, indicating strong demand for the company's robots [2] - Approximately 25% of Intuitive Surgical's revenue comes from new robot sales, while the majority is generated from parts and services, creating a stable income stream that grows with each new system sold [5] Group 2: Competitive Landscape - Medtronic, a competitor in the medical device sector, has a P/E ratio of 26, making it a more attractively valued option compared to Intuitive Surgical's P/E ratio of 64 [1][6] - Medtronic is developing its own surgical robot, Hugo, which is not as advanced as the da Vinci system but is progressing and presents a significant growth opportunity [6][7] - Medtronic's diversified portfolio as one of the largest medical device companies supports its entry into surgical robotics, and the FDA approved Hugo for use in the U.S. in late 2025 [7] Group 3: Investment Considerations - Medtronic offers a dividend yield of 2.9% and is approaching Dividend King status, with a history of annual dividend increases nearing 50 years [8] - A $10,000 investment in Medtronic could yield around 100 shares, and as the Hugo system's installed base expands over the next decade, the stock may see a higher valuation, providing both income and growth potential [9]

IRVINE, Calif.--(BUSINESS WIRE)--At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural heart disease can live longer, healthier lives. As part of this commitment, Edwards announced the impact and renewed vision for Every Heartbeat Matters, its signature global health initiative, to help 2 million more patients facing barriers worldwide access. ...

   Calgary, Alberta – TheNewswire - February 26, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced the formation of a Scientific Advisory Committee (SAC) to support the Company’s advancing clinical, regulatory, and commercialization strategy as it progresses toward late-stage development.The SAC will provide independent, multidisciplinary expertise across clinical trial design, regulato ...

NovoCure (NasdaqGS:NVCR) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristoph Brackmann - CFOEmily Bodnar - VP, Equity ResearchFrank Leonard - CEOIngrid Goldberg - Head of Investor RelationsWilliam F. Doyle - Executive ChairmanConference Call ParticipantsAlbert Augustinus - AnalystJason Bednar - Managing Director and Senior Research AnalystNone - AnalystNone - AnalystOperatorThank you for standing by. Welcome to the Novocure Fourth Quarter 2025 Earnings Call. At this time, all p ...

Butterfly Network (NYSE:BFLY) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsJohn Doherty - EVP and CFOJoseph DeVivo - Chairman and CEOJosh Jennings - Managing DirectorConference Call ParticipantsAndrew Brackmann - Equity Research AnalystBen Haynor - Senior Research AnalystChase Knickerbocker - Senior Equity Research AnalystOperatorHello, everyone, thank you for joining the Butterfly Network Inc. Q4 and FY 2025 earnings call. My name is Gabrielle, I will be coordinating your call to ...

Butterfly Network (NYSE:BFLY) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsJohn Doherty - CFOJoseph DeVivo - Chairman and CEOJosh Jennings - Managing DirectorConference Call ParticipantsAndrew Brackmann - Equity Research AnalystBen Haynor - Senior Research AnalystNone - AnalystOperatorHello, everyone, thank you for joining the Butterfly Network Inc. Q4 and FY 2025 earnings call. My name is Gabrielle, I will be coordinating your call today. During the presentation, you can register ...

PROCEPT BioRobotics (NasdaqGM:PRCT) 2026 Investor Day February 26, 2026 08:00 AM ET Company ParticipantsBarry Templin - EVP and CTOKevin Waters - EVP and CFOLarry Wood - CEOMatt Bacso - VP of Investor Relations and Business OperationsNathan Treybeck - Equity Research VPPooja Sharma - Chief Marketing and Strategy OfficerConference Call ParticipantsBrandon Vazquez - Research AnalystChris Pasquale - Partner and Senior Analyst of Medical Devices and SuppliesJosh Jennings - Managing Director and Senior AnalystSt ...